Literature DB >> 21917950

TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure.

Claudio Fenizia1, Brandon F Keele, David Nichols, Stefano Cornara, Nicolò Binello, Monica Vaccari, Poonam Pegu, Marjorie Robert-Guroff, Zhong-Min Ma, Christopher J Miller, David Venzon, Vanessa Hirsch, Genoveffa Franchini.   

Abstract

TRIM5α is a natural resistance factor that binds retroviral capsid proteins and restricts virus replication. The B30.2/SPRY domain of TRIM5α is polymorphic in rhesus macaques, and some alleles are associated with reduced simian immunodeficiency virus (SIV) SIV(mac251) and SIV(smE543) replication in vivo. We determined the distribution of TRIM5α alleles by PCR and sequence analysis of the B30.2/SPRY domain in a cohort of 82 macaques. Thirty-nine of these macaques were mock vaccinated, 43 were vaccinated with either DNA-SIV/ALVAC-SIV/gp120, ALVAC-SIV/gp120, or gp120 alone, and all were exposed intrarectally to SIV(mac251) at one of three doses. We assessed whether the TRIM5α genotype of the macaques affected the replication of challenge virus by studying the number of SIV variants transmitted, the number of exposures required, the SIV(mac251) viral level in plasma and tissue, and the CD4(+) T-cell counts. Our results demonstrated that TRIM5α alleles, previously identified as restrictive for SIV(mac251) replication in vivo following intravenous exposure, did not affect SIV(mac251) replication following mucosal exposure, regardless of prior vaccination, challenge dose, or the presence of the protective major histocompatibility complex alleles (MamuA01(+), MamuB08(+), or MamuB017(+)). The TRIM5α genotype had no apparent effect on the number of transmitted variants or the number of challenge exposures necessary to infect the animals. DNA sequencing of the SIV(mac251) Gag gene of the two stocks used in our study revealed SIV(mac239)-like sequences that are predicted to be resistant to TRIM5α restriction. Thus, the TRIM5α genotype does not confound results of mucosal infection of rhesus macaques with SIV(mac251).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917950      PMCID: PMC3209340          DOI: 10.1128/JVI.05707-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics.

Authors:  J W Romano; K G Williams; R N Shurtliff; C Ginocchio; M Kaplan
Journal:  Immunol Invest       Date:  1997 Jan-Feb       Impact factor: 3.657

2.  Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.

Authors:  David Perez-Caballero; Theodora Hatziioannou; Annie Yang; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells.

Authors:  Christopher M Owens; Peter C Yang; Heinrich Göttlinger; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing.

Authors:  L A Knapp; E Lehmann; M S Piekarczyk; J A Urvater; D I Watkins
Journal:  Tissue Antigens       Date:  1997-12

6.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.

Authors:  B Chackerian; E M Long; P A Luciw; J Overbaugh
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha.

Authors:  Hassan Javanbakht; Felipe Diaz-Griffero; Matthew Stremlau; Zhihai Si; Joseph Sodroski
Journal:  J Biol Chem       Date:  2005-05-15       Impact factor: 5.157

8.  Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.

Authors:  Matthew Stremlau; Michel Perron; Sohanya Welikala; Joseph Sodroski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Early replication block of human immunodeficiency virus type 1 in monkey cells.

Authors:  R Shibata; H Sakai; M Kawamura; K Tokunaga; A Adachi
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

10.  TRIM5 is an innate immune sensor for the retrovirus capsid lattice.

Authors:  Thomas Pertel; Stéphane Hausmann; Damien Morger; Sara Züger; Jessica Guerra; Josefina Lascano; Christian Reinhard; Federico A Santoni; Pradeep D Uchil; Laurence Chatel; Aurélie Bisiaux; Matthew L Albert; Caterina Strambio-De-Castillia; Walther Mothes; Massimo Pizzato; Markus G Grütter; Jeremy Luban
Journal:  Nature       Date:  2011-04-21       Impact factor: 49.962

View more
  29 in total

1.  Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Authors:  Rajeev Gautam; Yoshiaki Nishimura; Wendy R Lee; Olivia Donau; Alicia Buckler-White; Masashi Shingai; Reza Sadjadpour; Stephen D Schmidt; Celia C LaBranche; Brandon F Keele; David Montefiori; John R Mascola; Malcolm A Martin
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N.

Authors:  Madina Shakirzyanova; Lily Tsai; Wuze Ren; Agegneu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

3.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Authors:  Monica Vaccari; Shari N Gordon; Slim Fourati; Luca Schifanella; Namal P M Liyanage; Mark Cameron; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Erik Billings; Mangala Rao; Amy W Chung; Karen G Dowell; Chris Bailey-Kellogg; Eric P Brown; Margaret E Ackerman; Diego A Vargas-Inchaustegui; Stephen Whitney; Melvin N Doster; Nicolo Binello; Poonam Pegu; David C Montefiori; Kathryn Foulds; David S Quinn; Mitzi Donaldson; Frank Liang; Karin Loré; Mario Roederer; Richard A Koup; Adrian McDermott; Zhong-Min Ma; Christopher J Miller; Tran B Phan; Donald N Forthal; Matthew Blackburn; Francesca Caccuri; Massimiliano Bissa; Guido Ferrari; Vaniambadi Kalyanaraman; Maria G Ferrari; DeVon Thompson; Marjorie Robert-Guroff; Silvia Ratto-Kim; Jerome H Kim; Nelson L Michael; Sanjay Phogat; Susan W Barnett; Jim Tartaglia; David Venzon; Donald M Stablein; Galit Alter; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

4.  Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.

Authors:  Peng Xiao; L Jean Patterson; Seraphin Kuate; Egidio Brocca-Cofano; Michael A Thomas; David Venzon; Jun Zhao; Janet DiPasquale; Claudio Fenizia; Eun Mi Lee; Irene Kalisz; Vaniambadi S Kalyanaraman; Ranajit Pal; David Montefiori; Brandon F Keele; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 5.  New directions for HIV vaccine development from animal models.

Authors:  Michael B McChesney; Christopher J Miller
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

6.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events.

Authors:  Gregory Q Del Prete; Haesun Park; Christine M Fennessey; Carolyn Reid; Leslie Lipkey; Laura Newman; Kelli Oswald; Christoph Kahl; Michael Piatak; Octavio A Quiñones; W Gregory Alvord; Jeremy Smedley; Jacob D Estes; Jeffrey D Lifson; Louis J Picker; Brandon F Keele
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 8.  Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.

Authors:  Joern E Schmitz; Birgit Korioth-Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

Review 9.  Animal models for HIV/AIDS research.

Authors:  Theodora Hatziioannou; David T Evans
Journal:  Nat Rev Microbiol       Date:  2012-12       Impact factor: 60.633

10.  Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Authors:  Kara Jensen; Myra Grace Dela Pena-Ponce; Michael Piatak; Rebecca Shoemaker; Kelli Oswald; William R Jacobs; Glenn Fennelly; Carissa Lucero; Katie R Mollan; Michael G Hudgens; Angela Amedee; Pamela A Kozlowski; Jacob D Estes; Jeffrey D Lifson; Koen K A Van Rompay; Michelle Larsen; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.